Study of ivarmacitinib to prevent graft-versus-host disease after stem cell transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a new medicine called Ivarmacitinib to see if it can prevent graft-versus-host disease (a common complication after stem cell transplants where donor cells attack your body). This trial is for people with blood cancers who are planning a half-matched stem cell transplant and have not yet had intensive cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with a type of blood cancer, like leukemia or lymphoma.
- You are scheduled to have a stem cell transplant from a half-matched donor.
- You have not yet received any strong treatments for your cancer.
- You are generally able to take care of yourself and are not severely limited.
- You are either not of childbearing age, or you agree to use effective birth control during the study and for 6 months after.
- You do not have serious infections, heart, liver, or lung conditions, or other major medical problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This trial tests whether a new medication called gecacitinib can prevent a common complication after a stem cell transplant for myelofibrosis. The complication, called graft-versus-host disease, happens when donor cells attack the patient's body. The drug is given before and after the transplant.
This study tests a combination of three drugs (cyclophosphamide, sirolimus, and VIC-1911) to prevent graft-versus-host disease (GVHD), a common complication after a stem cell transplant. It is for children aged 8-18 with certain blood diseases who are undergoing a haploidentical stem cell transplant.
This study tests a new medicine called axatilimab, given after a stem cell transplant, to help prevent a common complication called graft-versus-host disease (GVHD), where the donor’s cells attack your body. If you are planning a transplant, this may help improve your recovery.
Hear when a new aGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.